Free tool
Drug Trial Radar: Ophthalmology
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
6
Active, not recruiting, industry sponsors, Ophthalmology, Phase 4 (post-approval)
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed188
6 trials
Showing 1 to 6, recently updated first.
- A Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular DegenerationActive, not recruiting
Astellas Pharma IncAstellas (ALPMY)
NCT06970665 · 17 participants · Start Jul 8, 2025 · Primary completion Jun 30, 2027
Drug: avacincaptad pegol · For: Geographic Atrophy; Age-Related Macular Degeneration
Sites: Fukushima, Japan; Kita-gun, Japan; Yokohama, Japan · 10 sites in all
- A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)Active, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT04853251 · 188 participants (planned) · Start Dec 14, 2021 · Primary completion Jul 30, 2027
Drug: LUCENTIS (Ranibizumab Injection) · For: Neovascular Age-related Macular Degeneration
Sites: Mesa, Arizona; Bakersfield, California; Huntington Beach, California · 40 sites in all
- A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular DegenerationPivotal-lookingActive, not recruiting
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT06795048 · 274 participants (planned) · Start Mar 14, 2025 · Primary completion Oct 16, 2026
Drug: Faricimab · For: Neovascular Age-related Macular Degeneration (nAMD)
Sites: Santa Ana, California; Orlando, Florida; Winter Haven, Florida · 67 sites in all
- A Study to Investigate Faricimab Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular EdemaActive, not recruiting
Genentech, Inc.Roche (Genentech) (RHHBY)
NCT05224102 · 218 participants (planned) · Start Feb 28, 2022 · Primary completion Jan 26, 2027
Drug: Faricimab · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Arcadia, California; Campbell, California · 43 sites in all
- A Study to Evaluate Corneal Endothelial Cell Density (ECD) in Subjects With Dry Eye Disease (DED) Administering Miebo® (Perfluorohexyloctane Ophthalmic Solution) for 12 Months.Pivotal-lookingActive, not recruiting
Bausch & Lomb IncorporatedIndustry
NCT06565650 · 216 participants · Start Jul 31, 2024 · Primary completion Nov 2025
Drug: Miebo; Saline · For: Dry Eye
Sites: Glendale, California; Murrieta, California; Newport Beach, California · 12 sites in all
- A Study of Intravitreal ILUVIEN® Implant as Baseline Therapy in Patients With Early Diabetic Macular Edema (DME)Pivotal-lookingActive, not recruiting
Alimera SciencesIndustry
NCT04469595 · 300 participants (planned) · Start Aug 31, 2020 · Primary completion Dec 31, 2024
Drug: Iluvien 0.19 MG Drug Implant; Aflibercept · For: Diabetic Macular Edema
Sites: Phoenix, Arizona; Tucson, Arizona; Beverly Hills, California · 40 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.